Day: February 24, 2022

Pliant Therapeutics to Participate in Upcoming Investor Conferences

Written by Customer Service on February 24, 2022. Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., Pliant’s President and Chief Executive Officer, will participate in the following conferences in March.Cowen 42nd Annual Health Care Conference: Dr. Coulie will participate in the Respiratory/ Infections panel on Tuesday, March 8, at 2:10 p.m. ET / 11:10 a.m. PT Oppenheimer 32nd Annual Healthcare Conference: Dr. Coulie will present a company update on Wednesday, March 16, at 3:20 p.m. ET / 12:20 p.m. PTInterested parties can access these presentations from the Investor Relations’ Events & Presentation page of Pliant’s website at https://ir.pliantrx.com/news-and-events/events-and-presentations...

Amerigo Reports Record Revenue, Net Income and Cash Balances in 2021

Written by Customer Service on February 24, 2022. Posted in Dividend Reports And Estimates.

2021 net income of $39.8 million, earnings per share of $0.22 (Cdn$0.28) Annual EBITDA1 of $90.1 million, annual operating cash flow before changes in non-cash working capital1 of $69.5 million Dividend of Cdn$0.03 per share payable on March 21, 2022 VANCOUVER, British Columbia, Feb. 24, 2022 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (TSX: ARG; ARREF:OTC) (“Amerigo” or the “Company”) is pleased to announce financial results for the year and three months (“Q4-2021”) ended December 31, 2021. Dollar amounts in this news release are in U.S. dollars unless indicated otherwise. Amerigo’s annual financial results included net income of $39.8 million, earnings per share (“EPS”) of $0.22 (Cdn$ 0.28), EBITDA1 of $90.1 million and operating cash flow before changes in working capital1 of $69.5 million. “Amerigo had a robust operational and...

Dynacor Declares March 2022 Monthly Dividend

Written by Customer Service on February 24, 2022. Posted in Dividend Reports And Estimates.

MONTREAL, Feb. 24, 2022 (GLOBE NEWSWIRE) — Dynacor Gold Mines Inc. (TSX: DNG) (Dynacor or the Corporation) announced its monthly dividend. The declaration of a dividend payment of C$0.0083 per common share will be payable on March 17, 2022, to shareholders of record as of the close of business on March 9, 2022. This dividend represents the twenty-fourth (24th) dividend and (14th) fourteenth monthly payment made to shareholders. The Corporation’s monthly dividend qualifies as an “eligible dividend” for Canadian income tax purposes. The payment and increase of dividends are at the discretion of the Board and will depend on the Corporation’s financial results, cash requirements, prospects and other factors deemed relevant by the Board. ABOUT DYNACOR Dynacor is a dividend-paying industrial gold ore processor headquartered in Montreal,...

Oma Savings Bank Plc’s Board of Directors decided on a new incentive scheme and an earning period for key persons for 2022-2023

Written by Customer Service on February 24, 2022. Posted in Public Companies.

OMA SAVINGS BANK PLC, STOCK EXCHANGE RELEASE 24 FEBRUARY 2022 AT 15.01 P.M. EET, OTHER INFORMATION DISCLOSED TO THE RULES OF THE EXCHANGEOma Savings Bank Plc’s Board of Directors decided on a new incentive scheme and an earning period for key persons for 2022-2023 The Board of Directors of Own Savings Bank Plc (OmaSp or the Company) has decided to establish a new share-based incentive scheme for key persons of the Group. The aim of the scheme is to combine the interests of owners and key persons in order to increase the value of the Company in the long term, and to commit the key persons to implement the Company’s strategy, objectives and long-term interest and to provide them with competitive earnings of the Company’s shares and a remuneration scheme based on accrual. The share-based incentive scheme is in place until...

Healthcare Triangle (HCTI) Closes Previously Announced Acquisition of DevCool, an Electronic Health Record (EHR) Focused Healthcare IT and Managed Services Company

Written by Customer Service on February 24, 2022. Posted in Mergers And Acquisitions.

Acquisition Expected to Add Approximately $20 Million in Revenues PLEASANTON, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — Healthcare Triangle, Inc. (HCTI), a leading provider of Healthcare and Life Sciences cloud transformation, managed services and data analytics platform company announced today that it has completed its previously announced acquisition of DevCool, Inc. (“DevCool”). DevCool provides EHR Implementation and Managed Services to 6 of the top 10 Hospitals in the US and specializes in providing services to cancer research hospitals and university medical centres. Healthcare Triangle completed the transaction for a total consideration of approximately $7.7 million. The acquisition is expected to add approximately $20 million in annual revenues and be accretive to EBITDA. Speaking of the acquisition, Suresh Venkatachari,...

StrikeForce Expands Into Brazil with New Distribution Partner

Written by Customer Service on February 24, 2022. Posted in Mergers And Acquisitions.

EDISON, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) — StrikeForce Technologies, Inc. (OTCQB: SFOR), a cyber security company that provides next-gen cyber, privacy & data protection solutions for consumers, corporations, & government agencies, announced today a new Reseller/Distributor agreement with Zentek corporation. “We are really excited about this announcement,” says Will Lynch, Director of Channel Distribution for StrikeForce, “Zentech provides an IT marketplace for Banks, Insurance carriers, Financial Services firms and ISPs, and they have been asked to integrate our GuardedID and MobileTrust into a bundle of services within an Insurance Company’s Personal Cyber Insurance policy. The initial launch is expected towards the end of Q2 into Q3”. “Brazil has one of the strongest economies in Latin America. Due to that fact,...

Troika Media Group to Acquire Converge Direct LLC, a Leading Digital and Offline Performance Media and Marketing Company, for $125 Million

Written by Customer Service on February 24, 2022. Posted in Mergers And Acquisitions.

Los Angeles, CA, Feb. 24, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Troika Media Group, Inc. (Nasdaq:TRKA): Financial Highlights: Converge Direct, LLC and its affiliated businesses (collectively, “Converge”) generated approximately $300 million of revenue and $23 million of adjusted EBITDA for the year ended December 31, 2021. Estimated combined adjusted EBITDA over $27 million for CY 2022. Significantly accretive to adjusted earnings per share. Following the closing, it is anticipated that the majority of the combined business’ revenue will be recurring. Increased margins per customer relationship without a significant increase in operating costs with positive client outcomes arising from deeper client engagements. Consolidated cost synergies of more than $2 million expected in the first year after closing. Cantor Fitzgerald...

Man Group PLC : Form 8.3 – John Menzies plc

Written by Customer Service on February 24, 2022. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: Man Group PLC(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree John Menzies plc(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening position...

ARYA Sciences Acquisition Corp IV and Amicus Therapeutics, Inc. Mutually Agree to Terminate Business Combination Agreement With Respect to the Acquisition of Amicus’ Gene Therapy Business Due to Market Conditions

Written by Customer Service on February 24, 2022. Posted in Public Companies.

NEW YORK, Feb. 24, 2022 (GLOBE NEWSWIRE) — ARYA Sciences Acquisition Corp IV (NASDAQ: ARYD) (“ARYA IV”), a publicly traded special purpose acquisition company sponsored by Perceptive Advisors announced today that, due to existing market conditions, it has mutually agreed with Amicus Therapeutics, Inc. (Nasdaq: FOLD) (“Amicus”) to terminate their previously announced Business Combination Agreement (the “Business Combination Agreement”), effective immediately. “While this is not the outcome we had hoped for, ARYA IV still has over a year remaining to identify and execute on a business combination transaction and the ARYA IV team believes it is well positioned to identify and execute on an opportunity that meets its key investment criteria and that can deliver value for its shareholders within that time period,” said Adam Stone,...

ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results

Written by Customer Service on February 24, 2022. Posted in Public Companies.

Additional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022 Phase 2/3 Sirius and Celeste clinical trials of ultevursen (QR-421a) in Usher syndrome and retinitis pigmentosa underway; interim data readout from Helia extension study of ultevursen planned by year-end 2022 Repeated dose study planned for QR-1123 for autosomal dominant retinitis pigmentosa and initial data from molecular proof-of concept biomarker study for QR-504a for Fuchs endothelial corneal dystrophy to be reported in 2022 Cash runway into mid-to-late 2024LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the...

Day: February 24, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice